Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | IDH2 | P48735 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29561209 | 1.00 | KCNH3 (0.52) | KCNH3MEN1LMNAKMT2ATDP1 | |
| SCHEMBL795751 | 0.89 | L3MBTL1 (0.45) | KCNH3MEN1LMNAKMT2ATDP1 | |
| SCHEMBL795752 | 0.84 | KMT2A (0.43) | MEN1LMNAKMT2ATDP1L3MBTL1 | |
| SCHEMBL795269 | 0.77 | EPHX2 (0.39) | MEN1LMNAKMT2ATDP1L3MBTL1 | |
| SCHEMBL808019 | 0.76 | SCN9A (0.39) | L3MBTL1NPSR1HDAC1HDAC8HDAC6 | |
| SCHEMBL29904100 | 0.75 | NPSR1 (0.36) | MEN1LMNAKMT2ATDP1L3MBTL1 | |
| SCHEMBL796256 | 0.74 | ROCK1 (0.42) | LMNAL3MBTL1CHRNA7HDAC1HDAC8 | |
| SCHEMBL3749726 | 0.74 | NR1H4 (0.50) | L3MBTL1NPSR1HDAC1HDAC8HDAC6 | |
| SCHEMBL807919 | 0.73 | MAPT (0.38) | MEN1KMT2AL3MBTL1CHRNA7MAPT | |
| SCHEMBL794750 | 0.73 | SYK (0.41) | MGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200079755-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2020-03-12 | — | — | US | claimed |
| US-10294215-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2019-05-21 | — | — | US | claimed |
| US-20170298045-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-10-19 | — | — | US | claimed |
| US-9732062-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | claimed |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | claimed |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2022-11-22 | — | — | US | disclosed |
| CN-108912066-B | Therapeutically active compounds and methods of use thereof | 安吉奥斯医药品有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3984997-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Les Laboratoires Servier SAS (FR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3406608-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | LES LABORATOIRES SERVIER SAS (FR) | 2021-09-15 | — | — | EP | disclosed |
| CN-107417667-B | Therapeutically active compounds and methods of use thereof | 安吉奥斯医药品有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20200079755-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2020-03-12 | — | — | US | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | KCNH3 1235/4885MEN1 4842/4885LMNA 4798/4885 |
| US-20200079755-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | KCNH3 4722/4885MEN1 1875/4885LMNA 1508/4885 |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | KCNH3 4722/4885MEN1 1875/4885LMNA 1508/4885 |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | KCNH3 4722/4885MEN1 1875/4885LMNA 1508/4885 |
| US-20170298045-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | KCNH3 4722/4885MEN1 1875/4885LMNA 1508/4885 |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | KCNH3 4722/4885MEN1 1875/4885LMNA 1508/4885 |
| US-10294215-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | KCNH3 4722/4885MEN1 1875/4885LMNA 1508/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | KCNH3 1235/4885MEN1 4842/4885LMNA 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.